Sir, Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is a more convenient, quicker and less expensive alternative to mediastinoscopy for sampling mediastinal lymph nodes and masses. Since its introduction, it has become well established as a further tool at the disposal of chest physicians by which to accurately diagnose and stage patients with suspected lung cancer and in the evaluation of those with mediastinal lymphadenopathy of uncertain aetiology.
1,2 Although its benefits, especially when compared to other investigative tools in lung cancer are well studied, far less is known regarding 'real-life' outcomes during its initial introduction. We therefore wished to highlight the demographics, results and diagnostic sensitivity of EBUS-TBNA in the first consecutive 100 patients in whom this procedure was performed at our institution.
One of two experienced bronchoscopists (G.P.C and M.C) began performing EBUS-TBNA in 2010; both had attended a 2-day course and observed during two separate lists at another institution. Since its introduction in Aberdeen Royal Infirmary, patient age, gender, length of procedure (from intubation to extubation), sedative doses, numbers of passes for each node and results have been recorded on consecutive patients. All of these (except one) was performed under light conscious sedation with the patient lying supine using an Olympus Keymed convex probe bronchoscope with biopsies taken using either a 21 or 22 gauge needle.
Of 100 patients, 66 were males with mean age 62 years (range 22-88 years). Mean procedure duration was 16 min, and median doses of midazolam and fentanyl were 4 mg and 100 mcg, respectively. One hundred and forty-two lymph nodes/masses were sampled with median number of passes of four per site. Lymphoid material was obtained from 126 (86%) of all sites sampled. A pathological abnormality was found in 73 patients; the majority of abnormalities were identified from cytological examination, with only 19% requiring further processing for histological evaluation. Results were as follows: non-small cell lung cancer (n = 34), small cell lung cancer (n = 20), granulomatous inflammation (n = 14), possible lymphoma (n = 1), metastatic squamous cell cancer of the neck (n = 1), metastatic urological cancer (n = 2) and metastatic breast cancer (n = 1). In the remaining 27 patients, no lymph node was sampled in 10 and lymph nodes were sampled in 17 cases with no abnormality detected; of the latter, 9 were subsequently considered to be true negatives. The overall diagnostic sensitivity for EBUS-TBNA for all 100 cases was 81% (77% in the first 50 patients sampled vs. 84% in the remainder). Samples were obtained from nine different lymph node stations and, in two cases, from biopsying circumferential tumour mass. The sampling frequency at each site and number of instances in which adequate tissue was successfully obtained is shown in Table 1 .
We have shown that with a minimal period of training, a variety of different cell types can be identified by the use of EBUS-TBNA with a diagnostic sensitivity of 80%. Moreover, the top of the learning curve was nearly reached after only 50 cases. Previous data have indicated that, across several European tertiary referral centres involving 500 patients in whom EBUS-TBNA was performed, the pooled sensitivity was 67%. 3 As the assessment of respiratory trainees is becoming increasingly important, it would therefore be reasonable to consider 
